Business Advisory Board
Chief Operating Officer & General Council, Kronos Bio
Barbara is the COO and General Council for Kronos Bio. Previous, Barbara was the international head of the firm’s life sciences practice and serves on Cooley’s management committee. Barbara has over 25 years of experience in counseling clients in the life sciences arena. Her clients range from early-stage startups to larger public companies, and include venture funds, investment banks and non-profit institutions.
Barbara advises clients on a variety of legal and business issues. Her particular expertise is in highly negotiated transactions, from complex strategic partnering transactions to mergers and acquisitions. She also represents companies and investors in private financings, strategic investments, spin-outs, and public offerings.
Some of Barbara’s recent representative transactions include NGM Pharmaceuticals’ strategic collaboration with Merck involving a broad sponsored research program in the areas of diabetes, obesity and other chronic indications, as well as substantial equity investment by Merck; the formation and financing of Outpost Medicine, a new company created to pursue the development and commercialization of TAK-233, a clinical stage compound licensed from Takeda; the out-licensing by Versartis, Inc. of the exclusive Japanese rights to somavaratan, its novel, long-acting rhGH product, to Teijin; the sale of Calibrium (founded by former founders of Mercadia Biotech), along with MB2, LLC (both founded by former founders of Mercadia Biotech), to Novo Nordisk; and Cell Medica’s exclusive collaboration and codevelopment partnership with the Baylor College of Medicine for the creation of next-generation cellular immunotherapy products for cancer.
Barbara is known for working closely with her clients as an integral part of the management team in setting strategic direction, and structuring and negotiating mission-critical transactions. Her combination of business and legal experience covers the full spectrum of transactions and issues facing Life Sciences and other healthcare companies.
In 2001, Barbara left the practice of law and served as the vice president, business development and general counsel of iScribe, Inc., a venture-backed healthcare IT startup, where she gained critical operating experience. Her company experience allows her to be especially attuned to the issues emerging company clients will face.
Barbara has served as a member of the BIO Emerging Companies’ Section Governing Board and has been a speaker at multiple life sciences-related conferences (Allicense; BIO, BIO Europe; BIO CEO & Investor Conference; BioEquity Europe; BIO Annual Meetings; etc.), as well as guest lecturer at University of California, Berkeley (Boalt Hall), and Stanford University on biotechnology law, biotech business models, corporate partnering negotiations and deal structures, and bioethics. Barbara is listed in The Best Lawyers in America 2008-2016, listed as “Band 1” attorney in the 2016 edition of Chambers USA: America’s Leading Lawyers for Business, listed in Northern California’s Super Lawyers from 2004 to 2013, was selected in as one of Lawdragon’s New Stars, New Worlds and in the Lawdragon 500 Leading Lawyers in America.
Barbara received a JD from University of California, Berkeley, Boalt Hall School of Law. She received her BA from Stanford University.